Home Featured Page 116

Featured

Latest

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

Bright Minds Biosciences Receives a Favorable Written Opinion from the International...

Be the Bridge at Psychedelic Science 2023

PT406 – Bicycle Day, Unveiling Entheon, and The Mystical Experience Through...

Numinus to Participate in a Water Tower Research Fireside Chat on...

Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S....

Opinions | The Church of Psilomethoxin: Fantasy Chemistry Gets Fact Checked

Numinus Launches New Website to Enhance its Client Experience

PT405 – The Psychedelic Medicine PAC: The Push for Federal Funding...

Numinus Wellness Inc. Reports Q2 2023 Results

atai Life Sciences Announces First Subject Dosed in the Phase 1...

EDITOR PICKS

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug...

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

Bright Minds Biosciences Receives a Favorable Written Opinion from the International...

Be the Bridge at Psychedelic Science 2023

PT406 – Bicycle Day, Unveiling Entheon, and The Mystical Experience Through...

Numinus to Participate in a Water Tower Research Fireside Chat on...

Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S....

Opinions | The Church of Psilomethoxin: Fantasy Chemistry Gets Fact Checked

Numinus Launches New Website to Enhance its Client Experience

PT405 – The Psychedelic Medicine PAC: The Push for Federal Funding...

Numinus Wellness Inc. Reports Q2 2023 Results

atai Life Sciences Announces First Subject Dosed in the Phase 1...

EDITOR PICKS

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug...

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY